The global antiemetic drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Antiemetic drugs are the medications that are used to treat nausea and vomiting. Both of these conditions are generally the symptoms of several medical issues such as food poisoning, pregnancy, motion sickness, dizziness, and sometimes even emotional stress. Adding to this, antiemetics drugs are also used for the treatment of the side effects of other medications such as chemotherapy, opioid analgesics, and general anesthetics. 

Further, growing geriatric population along with the rising prevalence of cancer as well as the growing number of gastroenteritis patients are also acting as the pivotal factors contributing to the increased demand for these drugs. The global antiemetic drugs market is also driven by extensive R&D along with new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is an antiemetic drug that is indicated for the control of severe nausea and vomiting.

Some major players in the market include GlaxoSmithKline plc, Merck & Co., Inc., and Novartis International AG, among others. These market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Class

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  GlaxoSmithKline plc, Merck & Co., Inc., and Novartis International AG, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Antiemetic Drugs Market Report by Segment

By Drug Class 

    • 5-HT3 Receptor Antagonists

    • Dopamine Antagonists

    • NK1 Receptor Antagonists

    • H1 Receptor Antagonists

    • Cannabinoids

    • Benzodiazepines

    • Anticholinergics

    • Steroids

By Application

    • Motion Sickness

    • Dizziness

    • General Anesthetics

    • Others

Global Antiemetic Drugs Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa